Xenetic Biosciences Inc (XBIO) USD0.001
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The Company's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.